Scientists at Johns Hopkins Medicine have discovered a new RNA modification, N4-acetylcytidine (ac4C), which may significantly enhance the efficacy of mRNA therapies. This finding suggests that ac4C could enable cells to produce more therapeutic proteins compared to the current standard, N1-methylpseudouridine (m1Ψ), used in COVID-19 vaccines.
The research indicates that ribosomes, which assemble proteins from mRNA, operate nearly twice as fast on ac4C-modified strands. This acceleration could resolve what researchers describe as a ‘traffic jam’ in protein production, potentially leading to more effective treatments with smaller doses.
If further studies confirm these results, the implications for the mRNA industry could be profound. Enhanced protein production could improve the effectiveness of vaccines and therapies for various diseases, including cancer and autoimmune conditions, while also reducing the required dosage.
As the field of mRNA technology continues to evolve, this small chemical modification could pave the way for the next generation of medicines, making treatments more efficient and accessible. The ongoing research will be crucial in determining whether ac4C can be safely implemented in clinical settings.
Source: Euronews
